IL242533B - Naltrexone cancer treatment - Google Patents
Naltrexone cancer treatmentInfo
- Publication number
- IL242533B IL242533B IL242533A IL24253315A IL242533B IL 242533 B IL242533 B IL 242533B IL 242533 A IL242533 A IL 242533A IL 24253315 A IL24253315 A IL 24253315A IL 242533 B IL242533 B IL 242533B
- Authority
- IL
- Israel
- Prior art keywords
- naltrexone
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title 1
- 229960003086 naltrexone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201308440A GB201308440D0 (en) | 2013-05-10 | 2013-05-10 | Therapeutic |
| PCT/GB2014/051439 WO2014181131A1 (en) | 2013-05-10 | 2014-05-12 | Treatment of cancer with naltrexone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL242533B true IL242533B (en) | 2020-10-29 |
Family
ID=48672126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL242533A IL242533B (en) | 2013-05-10 | 2015-11-10 | Naltrexone cancer treatment |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9895438B2 (enExample) |
| EP (1) | EP2994137B1 (enExample) |
| JP (1) | JP6346269B2 (enExample) |
| KR (1) | KR102162038B1 (enExample) |
| CN (1) | CN105451740B (enExample) |
| AU (1) | AU2014264445B2 (enExample) |
| BR (1) | BR112015028269A2 (enExample) |
| CA (1) | CA2912203C (enExample) |
| GB (1) | GB201308440D0 (enExample) |
| IL (1) | IL242533B (enExample) |
| MX (1) | MX2015015582A (enExample) |
| RU (1) | RU2686325C2 (enExample) |
| WO (1) | WO2014181131A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410216D0 (en) * | 2014-06-09 | 2014-07-23 | Cancer Vaccine Inst | Therapeutic |
| GB201704911D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
| CN111050801B (zh) * | 2017-03-28 | 2023-03-28 | Ldn制药有限公司 | 用于治疗癌症的增加bcl2-相关的细胞死亡激动剂表达的药剂 |
| WO2019055597A1 (en) * | 2017-09-13 | 2019-03-21 | National Tuberous Sclerosis Association, Inc. | Methods and compositions for the treatment of tsc |
| CA3113895A1 (en) * | 2018-11-01 | 2020-05-07 | Faron Pharmaceuticals Oy | Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages |
| WO2020178446A1 (en) * | 2019-03-06 | 2020-09-10 | LDN Pharma Limited | Method of monitoring treatment |
| GB201903546D0 (en) * | 2019-03-15 | 2019-05-01 | Ldn Pharma Ltd | Cancer treatment |
| AU2022211609A1 (en) * | 2021-01-25 | 2023-07-27 | LDN Pharma Limited | Naltrexone compositions |
| CN114836529B (zh) * | 2022-03-30 | 2023-05-30 | 唐颢 | Ogfr基因或其编码的蛋白在心肌损伤辅助诊断及治疗中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4689332A (en) * | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
| GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| US6136780A (en) * | 1996-03-29 | 2000-10-24 | The Penn State Research Foundation | Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor |
| EP0945133A1 (en) * | 1998-03-26 | 1999-09-29 | Lipha | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| US6288074B1 (en) * | 1998-11-17 | 2001-09-11 | Bernard Bihari | Method of treating lymphoproliferative syndrome |
| US6194382B1 (en) * | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
| US6384044B1 (en) * | 1999-11-29 | 2002-05-07 | Bernard Bihari | Method of treating cancer of the prostate |
| CN103405431B (zh) * | 2002-05-17 | 2016-04-13 | 台湾J药品有限公司 | 阿片和阿片样化合物及其用途 |
| US8017622B2 (en) * | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| GB0509052D0 (en) | 2005-05-04 | 2005-06-08 | Aimsco Ltd | Combination therapy |
| US20090191185A1 (en) * | 2006-04-26 | 2009-07-30 | The Uab Research Foundation | Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling |
| WO2011009015A1 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| EP2593095B1 (en) | 2010-07-16 | 2019-03-27 | Mallinckrodt LLC | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| GB201410216D0 (en) * | 2014-06-09 | 2014-07-23 | Cancer Vaccine Inst | Therapeutic |
| GB201704909D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
| GB201704911D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
-
2013
- 2013-05-10 GB GB201308440A patent/GB201308440D0/en not_active Ceased
-
2014
- 2014-05-12 AU AU2014264445A patent/AU2014264445B2/en active Active
- 2014-05-12 JP JP2016512422A patent/JP6346269B2/ja active Active
- 2014-05-12 KR KR1020157035176A patent/KR102162038B1/ko active Active
- 2014-05-12 EP EP14725506.1A patent/EP2994137B1/en active Active
- 2014-05-12 US US14/890,300 patent/US9895438B2/en active Active
- 2014-05-12 RU RU2015152785A patent/RU2686325C2/ru active
- 2014-05-12 WO PCT/GB2014/051439 patent/WO2014181131A1/en not_active Ceased
- 2014-05-12 MX MX2015015582A patent/MX2015015582A/es unknown
- 2014-05-12 CA CA2912203A patent/CA2912203C/en active Active
- 2014-05-12 BR BR112015028269A patent/BR112015028269A2/pt not_active Application Discontinuation
- 2014-05-12 CN CN201480033900.4A patent/CN105451740B/zh active Active
-
2015
- 2015-11-10 IL IL242533A patent/IL242533B/en active IP Right Grant
-
2018
- 2018-01-10 US US15/867,177 patent/US20180207263A1/en not_active Abandoned
-
2021
- 2021-10-22 US US17/508,590 patent/US20220040295A1/en not_active Abandoned
-
2023
- 2023-08-16 US US18/234,648 patent/US20230390388A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2912203A1 (en) | 2014-11-13 |
| EP2994137A1 (en) | 2016-03-16 |
| GB201308440D0 (en) | 2013-06-19 |
| US20220040295A1 (en) | 2022-02-10 |
| BR112015028269A2 (pt) | 2017-07-25 |
| WO2014181131A1 (en) | 2014-11-13 |
| NZ714999A (en) | 2021-05-28 |
| AU2014264445A1 (en) | 2016-01-07 |
| KR20160032013A (ko) | 2016-03-23 |
| CN105451740A (zh) | 2016-03-30 |
| KR102162038B1 (ko) | 2020-10-06 |
| JP6346269B2 (ja) | 2018-06-20 |
| RU2686325C2 (ru) | 2019-04-25 |
| CA2912203C (en) | 2021-08-17 |
| JP2016524602A (ja) | 2016-08-18 |
| CN105451740B (zh) | 2019-07-19 |
| MX2015015582A (es) | 2016-08-11 |
| EP2994137B1 (en) | 2022-12-14 |
| US20160106832A1 (en) | 2016-04-21 |
| US20180207263A1 (en) | 2018-07-26 |
| AU2014264445B2 (en) | 2019-08-15 |
| RU2015152785A (ru) | 2017-06-16 |
| US9895438B2 (en) | 2018-02-20 |
| US20230390388A1 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201506877B (en) | Methods of treating bladder cancer | |
| GB201322725D0 (en) | Cancer therapy | |
| IL240935A0 (en) | Methods of treating lung cancer | |
| SG11201508223YA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| IL242533B (en) | Naltrexone cancer treatment | |
| SG11201509707QA (en) | Cancer therapy | |
| SG11201508878WA (en) | Methods of treating cancer | |
| SG11201507847UA (en) | Cancer therapy | |
| EP3008212A4 (en) | Methods of treatment of cancer | |
| GB201304872D0 (en) | Treatment | |
| ZA201507762B (en) | Methods of treating cancer | |
| EP2961412A4 (en) | CANCER THERAPY | |
| GB201607581D0 (en) | Treatment of cancer | |
| EP3049078A4 (en) | Treatment of cancer | |
| GB201307310D0 (en) | Treatment | |
| PL3016948T3 (pl) | 2-acyloaminotiazole do leczenia nowotworów | |
| EP3007712A4 (en) | Treatment of cancer | |
| EP3013332A4 (en) | Cancer treatment | |
| GB201518731D0 (en) | Tumour Therapy | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201322346D0 (en) | Combination treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |